Utilizing The GPEx Suite Of Technologies For Cell Line Development

Biopharmaceutical products in development continue to increase in complexity, which poses a challenge for pharmaceutical companies looking to improve speed and efficiency of biologic development. Cell line development is a critical step in the development process, impacting protein quality, manufacturing scalability/efficiency and timelines. The GPEx^® suite of cell line development technologies has been utilized to develop hundreds of proteins, including difficult-to-express proteins, in a variety of mammalian cell lines. The GPEx platform is particularly beneficial for complex proteins, such as multi-specific antibodies, unique protein fusions, bioconjugates (including ADCs), proteins requiring cleavage and proteins requiring other post-translational modification not typically performed by CHO cells.